adoptive tumor immunotherapy 肿瘤过继性免疫治疗
CONCLUSION: CIK cells have strong proliferative ability and higher cytotoxicity to tumor cells in vitro, which could be used as a potential anti-tumor adoptive immunotherapy in clinic.
结论：CIK细胞在体外扩增能力强，对肿瘤细胞的杀伤活性高，有望成为新一代抗肿瘤过继免疫细胞制剂而应用于临床。
This research is going to studying the anti-tumor activity of tumor antigen induced cord blood cells based on the definition of adoptive immunotherapy.
本研究正是从过继性免疫细胞治疗的概念出发，探讨肿瘤抗原诱导的脐血细胞的抗肿瘤效应。
The cell used in adoptive immunotherapy must have strong cytotoxic and proliferative ability, so CIK cell is thought of the new generation anti-tumor adoptive immunity treatment.
用于过继免疫治疗的活性细胞必须具有较强的细胞活性和增殖力，CIK细胞被认为是新一代抗肿瘤过继细胞免疫治疗的首选方案。
应用推荐